---
title: "Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297041490.md"
description: "Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00. According to TipRanks, Walsh is ranked #2719 out of 12443 analysts. In addition to Roth MKM, Arcturus Therapeutics also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued on August 20. However, on August 11, H.C. Wainwright maintained a Hold rating on Arcturus Therapeutics (NASDAQ: ARCT)."
datetime: "2026-08-26T11:55:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297041490.md)
  - [en](https://longbridge.com/en/news/297041490.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297041490.md)
generator: "portal-rs"
---

# Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)

Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00.

According to TipRanks, Walsh is ranked #2719 out of 12443 analysts.

In addition to Roth MKM, Arcturus Therapeutics also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued on August 20. However, on August 11, H.C. Wainwright maintained a Hold rating on Arcturus Therapeutics (NASDAQ: ARCT).

### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

- [Arcturus Therapeutics Q3 net loss narrows, revenue rises](https://longbridge.com/en/news/304524499.md)
- [ARCT: 2027 brings CF and OTC data catalysts, with LUNAR 2.0 driving the next pipeline phase](https://longbridge.com/en/news/304903138.md)
- [Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency](https://longbridge.com/en/news/299948643.md)
- [Nebius Group Draws Fresh Scrutiny Over AI Data Center Permits](https://longbridge.com/en/news/304920937.md)
- [Oklo Posts Higher Q3 Net Loss, Aurora-ID Construction Moves Toward Structural Work](https://longbridge.com/en/news/304881892.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**